| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q3 2017 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ROYALTY PHARMA PLC | 12 | Q3 2023 | 87.5% |
| ADC THERAPEUTICS SA SHS | 12 | Q3 2023 | 9.8% |
| FIBROGEN INC | 12 | Q3 2023 | 5.7% |
| COSTCO WHSL CORP NEW | 12 | Q3 2023 | 0.5% |
| WALMART INC | 12 | Q3 2023 | 0.5% |
| Sysco Corporation | 12 | Q3 2023 | 0.5% |
| Exxon Mobil Corporation | 12 | Q3 2023 | 0.5% |
| Chevron Corporation | 12 | Q3 2023 | 0.5% |
| KROGER CO | 12 | Q3 2023 | 0.5% |
| CVS Health Corporation | 12 | Q3 2023 | 0.5% |
View Vantage Consulting Group Inc's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| SYNTAX ETF TRUST | September 11, 2023 | 717,132 | 52.2% |
| SYNTAX ETF TRUST | November 08, 2022 | 156,133 | 56.8% |
| SYNTAX ETF TRUSTSold out | June 24, 2021 | 0 | 12.4% |
View Vantage Consulting Group Inc's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13G/A | 2023-09-11 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-10 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| SC 13G/A | 2022-11-08 |
| SC 13G/A | 2022-10-04 |
| SC 13G/A | 2022-09-12 |
View Vantage Consulting Group Inc's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.